*Ruiz Department of Ophthalmology and Visual Science, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth)
§Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine
∥Department of Anesthesiology, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Houston
¶Eye Center of Texas, Bellaire, TX
†Devers Eye Institute, Legacy Research Institute, Portland, OR
‡Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL
#Department of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, WV
**Southern Eye Group of Alabama, Mobile, AL
††Department of Ophthalmology, Icahn School of Medicine at Mount Sinai
§§Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY
‡‡Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Palm Beach Gardens, FL
∥∥Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA
This work was supported by an American Glaucoma Society Challenge Grant (San Francisco, CA); Research to Prevent Blindness (New York, NY); NIH/NEI Vision Core Grants P30EY028102 and P30EY010608 (Bethesda, MD); NIH/NCATS grants UL1 TR000371, UL1 TR000445, and UL1 TR001105 (Bethesda, MD); and NIH/NCATS Colorado CTSA Grant Number UL1TR002535 (REDCap). The sponsors or funding organizations had no role in the design or conduct of this research. The contents of this publication are the authors’ sole responsibility and do not necessarily represent official NIH views.
Disclosure: Dr R.L.G. reports personal fees from Aerie during the conduct of the study; membership of Data and Safety Monitoring Board for Glauckos and consultant and stockholder for Intelligent Retinal Imaging Systems, outside the submitted work. Dr D.S.G. reports personal fees (consultant) from Allergan, Alcon, Aerie, and Eyenovia outside the submitted work. Dr L.R.P. reports grants from NIH, The Glaucoma Foundation, and Research to Prevent Blindness, as well as personal fees from Eyenovia, Twenty-Twenty, and Skye Biosciences outside the submitted work. Dr S.L.M. reports a research grant from AbbVie and the National Eye Institute (outside the submitted work); and consulting fees from Nicox and Thea. Dr A.P.T. reports grants or contracts from Google and Research to Prevent Blindness (to Northwestern University); consulting fees from Ivantis, Sandoz, and Zeiss; and payment for expert testimony from Ivantis. Dr R.N.W. reports personal fees (consultant) from Abbvie, Allergan, Amydis, Aerie, Equinox, Eyenovia, Iantrek, Implandata, IOPtic, Nicox, Perivision, Topcon Medical. He reports research support from the National Eye Institute, National Institute of Minority Health and Health Disparities, Bausch + Lomb, Heidelberg Engineering, Zeiss-Meditec, Optovue, Centervue, and Topcon. Dr R.M.F. reports personal fees from Bausch and Lomb and Catawba; stock in 4DMD; and grants from Santen and Ivantis outside the submitted work. Dr L.S.B. reports personal fees (consultant) from Allergan, Abbive and Aerie outside the submitted work. The remaining authors declare no conflict of interest.
Reprints: Robert M. Feldman, MD, Robert Cizik Eye Clinic, 6400 Fannin St., Suite #1800, Houston, TX 77030 (e-mail: [email protected]).
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.glaucomajournal.com.